ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Clinical Alert Urges Patients To Seek Care From Specialists.

January 20, 2006

ACCC Asks More Community Representation, Clear Separation From Centers In New NCI Division

June 29, 1979

FDA Approves Aranesp For Chemo-Induced Anemia

August 30, 2002

ACS Stirs Discord By Placing Its Own Logo On A Coalition’s Petition, Then Reconsiders

February 7, 1997

Annual Report Key Element In Prevention Drive, Maquire Insists

February 2, 1979

Jerome Yates Named VP For Research At ACS

February 8, 2002